Skip to main content

Table 1 Baseline patient data (n = 82)

From: Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis

Clinical variable

HIPEC (n = 37)

Non-HIPEC (n = 45)

P

Sex, n (%)

 Male

21 (56.8)

27 (60.0)

0.767

 Female

16 (43.2)

18 (40.0)

 

Age (years, mean±SD)

63.6±7.0

61.6±7.8

0.283

KPS, n (%)

 ≥70

33 (91.9)

39 (86.7)

0.724

 60

3 (8.1)

6 (13.3)

 

PCI, (scores, mean±SD)

12.86±6.19

13.09±7.45

0.884

PCI, n (%)

 <20

29 (78.4)

34 (75.6)

0.763

 ≥20

8 (21.6)

11 (24.4)

 

Degree of ascites, n (%)

 Small or no

22 (59.5)

29 (64.4)

0.751

 Moderate

10 (27.0)

9 (20.0)

 

 Large

5 (13.5)

7 (15.6)

 

Distant metastasis, n (%)

 Yes

7 (18.9)

9 (20.0)

0.902

 No

30 (81.1)

36 (80.0)

 

Site of primary, n (%)

 Right colon

9 (24.3)

7 (15.6)

0.713

 Left colon

17 (45.9)

24 (53.3)

 

 Sigmoid

6 (16.2)

6 (13.3)

 

 Rectum

5 (13.5)

8 (17.8)

 

Targeted drug, n (%)

 Yes

12 (32.4)

9 (20.0)

0.199

 No

25 (67.6)

36 (80.0)

 
  1. HIPEC hyperthermic intraperitoneal chemotherapy, KPS Karnofsky performance scale, PCI peritoneal cancer index